Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
IRVINE, Calif., May 06, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Lion Biotechnologies, Inc. (“Lion” or the “Company”) (Nasdaq:LBIO). Investors who purchased or otherwise acquired shares between November 14, 2013 and April 10, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the June 13, 2017 lead plaintiff motion deadline.
If you purchased Lion shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint alleges that throughout the Class Period, Lion made false and/or misleading statements and/or failed to disclose: that Lion, through its former Chief Executive Officer (“CEO”) Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company when, in fact, they were paid promotions; that former CEO Singh engaged a notorious stock promotion firm to pay writers to publish articles about the Company on investment websites and to coordinate the distribution of articles to thousands of electronic mailboxes; that former CEO Singh actively participated in the promotional work for Lion Biotechnologies and understood that the promotion firm was using writers who would not disclose that Lion was indirectly compensating them for their publications; and that as a result of the above, Lion’s public statements were materially false and misleading at all relevant times. When this information was released to the public, Lion’s stock price dropped materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
